A decade after it was taken private by current chief executive Carolyn Cross, Ondine Biomedical Inc has returned to AIM. The previous AIM quotation was cancelled on 7 September 2011 and the TSX listing was also cancelled. The value of the deal was C$3.19m and the flotation value is more than 50 times that, although it does include new money.
Hospital acquired infections is an enormous potential market. Revenues are starting to accelerate as the company’s first product is being used in Canadi...
You are unauthorized to view this page.